SecBot SecBot
8-K ·Filed May 4, 2026

CABA

Cabaletta Bio, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago SEC0001193125-26-202389
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor the ASGCT presentation on May 14 for full data. Early signs of activity without preconditioning could de-risk the program, but sample is too small to draw conclusions. Expect volatility around the event.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.83
T+0 close · May 4, 2026 · via day close
Latest settled
−31.59%
T+60 · $2.62
Vs SPY
−33.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $3.83entry
  2. T+1 · 7mo ago +8.36%α +7.56% · $4.15
  3. T+5 · 6mo ago −0.26%α −3.20% · $3.82
  4. T+20 · 6mo ago −4.18%α −9.82% · $3.67
  5. T+60 · 4mo ago −31.59%α −33.45% · $2.62

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patients treated with rese-cel without preconditioning in the RESET-PV trial at ASGCT 2026. The data showed biologic activity in 2 of 4 patients and a favorable safety profile, but the sample is small and early-stage. No financial impact or guidance changes were disclosed.

Key Facts

  • Data from 4 refractory pemphigus vulgaris patients receiving lowest-dose rese-cel without preconditioning will be presented at ASGCT on May 14, 2026.
  • 2 of 4 patients demonstrated compelling clinical activity through 6 months; 3 of 4 remained off all immunomodulators and steroids.
  • Complete peripheral B cell elimination observed in 3 of 4 patients; one Grade 1 CRS, no ICANS.
  • Higher dose cohort in RESET-PV has been enrolled; durability data expected in H2 2026.
  • Initial dose cohort of RESET-SLE (lupus) is fully enrolled; initial data expected in H1 2026.

Financial Impact

No financial figures disclosed; pre-revenue biotech.

Risk Factors

  • Small sample size (n=4) limits statistical reliability.
  • Early-stage data may not replicate in larger cohorts.
  • No financial data or guidance provided; stock may move on sentiment alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-202389
Document: 0001193125-26-202389-index-headers.html0001193125-26-202389
Document: 0001193125-26-202389-index.html0001193125-26-202389
Document: 0001193125-26-202389.txt0001193125-26-202389

Track record

29 reports on CABA

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026